...
首页> 外文期刊>Bone marrow transplantation >Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias.
【24h】

Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias.

机译:慢性粒细胞白血病在第一个慢性期对α-干扰素无反应:自体移植后的结局和预后因素。 EBMT慢性白血病工作组。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We report the data obtained from the European Bone Marrow Transplant Registry for patients with CML who received autologous transplantation (AT) in chronic phase (CP) because alpha-IFN was ineffective. Forty-one CML patients (median age: 40.5 years; median Sokal index: 0.78) were included in this study. Bone marrow (16 cases) or blood (25 cases) progenitor cells were collected at diagnosis in 19 patients, during stable chronic phase or while the patient had cytogenetic (Cy) or complete hematologic response (CHR) in the other 22, and were manipulated ex vivo in 10 cases. The conditioning regimen consisted of busulfan associated with other chemotherapeutic regimens in 36 cases. Two patients died from interstitial pneumonitis (one case) and hemorrhage (one case). From the date of AT, the estimated probability of survival for the 41 patients was 84 +/- 13% and 51 +/- 29% at 2 and 4 years, respectively. Considering the 39 evaluable patients, the actuarial probability of achieving CHR, major and complete CyR 2 years after AT was 92 +/- 9%, 46 +/- 17%, and 30 +/- 15%, respectively. The Sokal score at diagnosis and the achievement of hematologic response after transplant were of prognostic importance. We suggest that a significant proportion of CML patients not responding to alpha-IFN may benefit from AT.
机译:我们报告从欧洲骨髓移植注册处获得的数据,该研究针对因α-IFN无效而在慢性期(CP)接受自体移植(AT)的CML患者。这项研究包括了41名CML患者(中位年龄:40.5岁;中位索卡尔指数:0.78)。在诊断时,在稳定的慢性期或在另外22例患者具有细胞遗传学(Cy)或完全血液学反应(CHR)时,在诊断时收集了19例患者的骨髓(16例)或血液(25例)的祖细胞,并对其进行了操作离体10例。调理方案由白消安与其他化疗方案相关,共36例。 2例患者死于间质性肺炎(1例)和出血(1例)。从AT的日期开始,这41名患者在2年和4年时的估计生存率分别为84 +/- 13%和51 +/- 29%。考虑到39位可评估患者,AT后2年实现CHR,主要和完全CyR的精算机率分别为92 +/- 9%,46 +/- 17%和30 +/- 15%。诊断时的Sokal评分和移植后血液学反应的实现对预后具有重要意义。我们建议对α-IFN无反应的CML患者中有很大一部分可能会从AT中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号